

## Fact sheet – Code Commission

# 20 June 2016 – disclosure in accordance with the PCC is getting closer!

It is well known that the **Pharma Cooperation Code (PCC)** regulates the relationships between pharmaceutical companies and doctors, pharmacies, hospitals, research institutes and patient organisations and **requires that payments between these parties are disclosed**.

EFPIA and scienceindustries request companies **not to disclose this information before 20 June 2016**. It will therefore be important to coordinate all communications on the matter, as many national associations – as well as scienceindustries – plan to announce the transparency initiative and briefly reiterate its content in a **press release** beforehand. The **press release from scienceindustries will be published shortly before 20 June 2016**, in calendar week 24.

scienceindustries will use the remaining time to make contact with various organisations of healthcare providers (in particular the FMH, the Conference of Cantonal Medical Societies (KKA), Pharmasuisse and H+) in order to explain the transparency initiative once again and foster a better understanding of it in these circles. The Q&A document with questions about communications has also been shared not just with the signatory companies but also with these organisations so that they will have access to the industry's answers to potential questions from the media. Responding to questions as consistently as possible will enable the public to form a coherent opinion on this issue and will reduce the risk of communication between the pharmaceutical industry and healthcare providers becoming confrontational.

We would like to reiterate that all pecuniary benefits that must be disclosed under the PCC must be published on signatory companies' websites by **30 June 2016 at the latest**. In order to achieve a high degree of transparency, disclosure must be as **individual** as possible – i.e. the recipient must be named personally – which requires the **consent of the persons or organisations affected**. scienceindustries will continue to raise awareness of the transparency initiative by making contact with healthcare provider organisations and emphasise its necessity, with the aim of convincing more exponents that this is the right course of action.

### Further information on the topic:

- [scienceindustries: disclosure from 2016](#)
- [Membernet: Pharma Codes section](#)